InfuSystem Holdings, Inc. filed its Form 10-Q with the SEC on November 9, 2026, reporting unaudited financial results for the quarterly period ended September 30, 2026, listed on NYSE American under the ticker INFU.

Key Highlights

  • Net revenues of $37,589 thousand for the three months ended September 30, 2026, compared with $36,488 thousand in the same period of 2025, according to the filing.
  • Net income of $3,156 thousand for the third quarter of 2026, up from $2,259 thousand in the third quarter of 2025, as reported in the condensed consolidated statements of operations.
  • Diluted earnings per share of $0.15 for Q3 2026, versus $0.11 in Q3 2025, based on diluted weighted average shares outstanding of 21,072,355.
  • Nine-month net income of $7,404 thousand for the period ended September 30, 2026, compared with $4,591 thousand for the same period in 2025.
  • Total assets of $104,519 thousand as of September 30, 2026, up from $100,560 thousand as of December 31, 2025.
  • Share repurchases totaling $4,963 thousand were made under the share repurchase program during the nine months ended September 30, 2026, per the stockholders' equity statement.
  • 20,033,488 shares outstanding as of November 8, 2026, as disclosed on the cover page of the filing.

InfuSystem Q3 2026 Financial Results: Revenue Growth and Improved Profitability

According to the filing, InfuSystem Holdings, Inc. (NYSE American:INFU) reported net revenues of $37,589 thousand for the three months ended September 30, 2026, an increase from $36,488 thousand in the comparable prior-year quarter. Gross profit for the third quarter of 2026 was $21,727 thousand, compared with $20,820 thousand in Q3 2025. Operating income for the quarter reached $4,746 thousand, up from $3,811 thousand in the year-ago period, the filing disclosed.

For the nine months ended September 30, 2026, the company reported net revenues of $108,206 thousand versus $107,206 thousand for the nine months ended September 30, 2025, according to the condensed consolidated statements of operations. Nine-month gross profit was $62,822 thousand compared with $59,861 thousand a year earlier. Net income for the nine-month period was $7,404 thousand, or $0.35 diluted earnings per share, versus $4,591 thousand, or $0.22 diluted earnings per share, in the prior-year period.

The condensed consolidated balance sheet as of September 30, 2026 showed total stockholders' equity of $64,150 thousand, up from $57,326 thousand as of December 31, 2025. The retained deficit narrowed to $58,261 thousand from $60,702 thousand at year-end 2025. Cash and cash equivalents were $9,108 thousand as of September 30, 2026, compared with $3,186 thousand as of December 31, 2025. Long-term debt stood at $19,687 thousand as of September 30, 2026. During the nine months ended September 30, 2026, the company repurchased 525 thousand shares under its share repurchase program for $4,963 thousand, and also repurchased shares to satisfy minimum statutory tax withholding obligations of $798 thousand, per the stockholders' equity statement.

What Was Disclosed

InfuSystem Holdings filed its quarterly report covering the period ended September 30, 2026, disclosing increases in net revenues, net income, and total stockholders' equity compared with both the prior quarter and the nine-month period ended September 30, 2025, along with balance sheet and share repurchase activity.